%0 Journal Article
%A Hesse, Robert
%A Gertzen, Christoph G. W.
%A Schmuck, Jessica Felice
%A Böcker, Justin Darvin
%A Pandey, Piyush
%A Behn, Tobias
%A Ruth, Christopher
%A Riesner, Detlev
%A Kath-Schorr, Stephanie
%A Lang, Philipp A.
%A Gohlke, Holger
%A Etzkorn, Manuel
%T The coming of age of DNA‐based catalysts for therapeutic applications
%J Clinical and translational medicine
%V 15
%N 7
%@ 2001-1326
%C Hoboken, NJ
%I Wiley
%M FZJ-2025-03758
%P e70408
%D 2025
%X DNA enzymes, also known as DNAzymes (Dz), are synthetic high-precision biocatalysts that have been identified by in vitro selection three decades ago.1 Dz are usually short, single-stranded DNA molecules that catalyse chemical reactions through their specific three-dimensional structure.2 Due to their enormous therapeutic potential, particular interest has been invested in RNA-cleaving Dz, such as the 8–17 Dz and 10–23 Dz2. In general, these DNAzymes share a modular architecture comprising a (conserved) catalytic loop sequence and adaptable substrate binding arm sequences that, following specific design guidelines, can be modified to bind virtually any given target RNA with high selectivity.
%F PUB:(DE-HGF)16
%9 Journal Article
%R 10.1002/ctm2.70408
%U https://juser.fz-juelich.de/record/1046238